Income Statement
TRANSCODE THERAPEUTICS, INC.
RNAZ
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|
|
Revenue
|
- | - | - | - |
|
Cost of Revenue
|
- | - | - | - |
|
Gross Profit
|
- | - | - | - |
|
Operating Expenses
|
15.66 | 19.42 | 18.67 | 6.15 |
|
Research & Development
|
9.71 | 12.26 | 10.23 | 2.75 |
|
Selling, General & Administrative
|
5.95 | 7.15 | 8.43 | 3.40 |
|
Other Operating Expenses
|
- | - | - | - |
|
Operating Income
|
-15.66 | -19.42 | -18.67 | -6.15 |
|
Non-Operating Income
|
-1.09 | 0.87 | 1.10 | -0.69 |
|
Interest Income
|
0.00 | 0.01 | 0.02 | 0.00 |
|
Interest Expense
|
0.03 | 0.06 | - | 0.10 |
|
Other Non-Op Income / Expense
|
- | - | - | - |
|
Income Before Tax
|
- | - | - | - |
|
Income Tax Expense
|
- | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - |
|
Net Income
|
-16.75 | -18.55 | -17.56 | -6.84 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - |
|
EBITDA
|
-15.66 | -19.42 | -18.67 | -6.15 |
|
Earnings Per Share (Basic)
|
-47.14 | -103.61 | -1.35 | -0.81 |
|
Diluted EPS
|
-47.14 | -103.61 | -1.35 | -0.81 |
|
Weighted Average Shares
|
0.36 | 0.18 | 12.98 | 8.43 |
|
Diluted Weighted Avg Shares
|
0.36 | 0.18 | 12.98 | 8.43 |
|
Comprehensive Income
|
- | - | - | - |